Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to conventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by antiangiogenic mechanisms of action and the absence of high-grade adverse effects commonly seen with MTD chemotherapy. However, similar to other anticancer therapies, inherent resistance to LDM chemotherapy is common. Moreover, even tumors that initially respond to metronomic regimens eventually develop resistance through mechanisms that are as yet unknown. Thus, we have developed in vivo models of PC-3 human prostate cancer cells resistant to extended LDM cyclophosphamide therapy. Such PC-3 variants show stable resistance to LDM cyclophosphamide in vivo yet retain in vitro sensitivity to 4-hydroperoxy-cyclophosphamide (precursor of the active cyclophosphamide metabolite 4-hydroxy-cyclophosphamide) and other chemotherapeutic agents, namely, docetaxel and doxorubicin. Moreover, LDM cyclophosphamide-resistant PC-3 variants remain sensitive to MTD cyclophosphamide therapy in vivo. Conversely, PC-3 variants made resistant in vivo to MTD cyclophosphamide show varying levels of resistance to metronomic cyclophosphamide when grown in mice. These results and additional studies of variants of the breast cancer cell line MDA-MB-231 suggest that resistance to LDM cyclophosphamide is a distinct phenomenon from resistance to MTD cyclophosphamide and that LDM cyclophosphamide administration does not select for MTD chemotherapy resistance. As such, our findings have various implications for the clinical use of metronomic chemotherapy.
Molecular and Cellular Biology Research, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada. urban.emmenegger@sunnybrook.ca
Urban
U
Emmenegger
Giulio
G
Francia
Annabelle
A
Chow
Yuval
Y
Shaked
Andrew
A
Kouri
Shan
S
Man
Robert S
RS
Kerbel
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D051379:Mice; D009368:Neoplasm Transplantation; D047368:Tumor Burden / Q000187:drug effects; D014407:Tumor Cells, Cultured
D003520:Cyclophosphamide
Cancer Res. 2002 May 15;62(10):2731-5
12019144
Nat Rev Cancer. 2008 Mar;8(3):180-92
18273037
Onkologie. 2007 Dec;30(12):606-8
18063872
J Clin Oncol. 1997 Jan;15(1):368-81
8996164
Nat Rev Cancer. 2008 Aug;8(8):592-603
18650835
Drug Resist Updat. 2005 Oct;8(5):271-97
16154799
N Engl J Med. 2008 May 8;358(19):2039-49
18463380
Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
19636328
Science. 2006 Sep 22;313(5794):1785-7
16990548
J Clin Oncol. 2010 Apr 20;28(12):2051-7
20308655
Clin Cancer Res. 2002 Jan;8(1):221-32
11801563
Cancer Res. 2004 Jun 1;64(11):3994-4000
15173013
Cancer Microenviron. 2008 Dec;1(1):159-70
19308694
J Cell Biochem. 1994 Sep;56(1):37-47
7806590
J Clin Oncol. 2009 Mar 20;27(9):1368-74
19204202
Cancer Res. 2006 Feb 1;66(3):1664-74
16452226
Ann Oncol. 2010 May;21 Suppl 5:v15-9
20555067
Breast Cancer Res. 2005;7(6):252-4
16280051
J Proteomics. 2010 May 7;73(7):1342-54
20219715
J Clin Oncol. 2005 Feb 10;23(5):939-52
15557593
Pharmacology. 2008;81(4):275-300
18259091
Am J Pathol. 2001 Apr;158(4):1325-34
11290550
J Clin Invest. 2000 Apr;105(8):R15-24
10772661
Mol Cancer Ther. 2007 Aug;6(8):2280-9
17671082
Science. 2002 Feb 22;295(5559):1526-8
11859195
Br J Cancer. 2008 May 6;98(9):1515-24
18382425
Anticancer Drugs. 2006 Sep;17(8):961-7
16940806
Neoplasia. 2010 Mar;12(3):264-74
20234820
Nat Rev Clin Oncol. 2009 Oct;6(10):569-79
19736552
BMC Cancer. 2009 Sep 28;9:347
19785749
Cancer Res. 2002 Apr 1;62(7):1931-4
11929804
Nature. 2005 Dec 15;438(7070):932-6
16355210
Nat Rev Clin Oncol. 2010 Aug;7(8):455-65
20531380
Lancet. 2009 May 16;373(9676):1662-3
19447241
Cancer Res. 2005 Aug 15;65(16):7045-51
16103050
Clin Cancer Res. 2009 Aug 15;15(16):5020-5
19671869
J Magn Reson Imaging. 2002 Oct;16(4):430-50
12353258
Recent Results Cancer Res. 2010;180:165-83
20033383
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
J Hepatol. 2010 Jul;53(1):126-31
20416968
Cancer Res. 2002 Dec 1;62(23):6938-43
12460910
Drug Resist Updat. 2004 Aug-Oct;7(4-5):289-300
15533766
J Neurooncol. 2009 Feb;91(3):329-36
18953493
Clin Cancer Res. 2009 Oct 15;15(20):6358-66
19825954
Lancet Oncol. 2010 Apr;11(4):350-7
20163987
Biochem J. 1978 Sep 1;173(3):773-86
213051
Nat Rev Cancer. 2004 Jun;4(6):423-36
15170445
Neoplasia. 2005 Jul;7(7):678-87
16026647
N Engl J Med. 2004 Apr 22;350(17):1713-21
15102997
Cancer Res. 2000 Apr 1;60(7):1878-86
10766175
Cancer Treat Rev. 2008 Dec;34(8):710-8
18620815